Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kerber Romy, Lorenz Eva, Duraffour Sophie, Sissoko Daouda, Rudolf Martin, Jaeger Anna, Cisse Sekou Ditinn, Camara Alseny-Modet, Miranda Osvaldo, Castro Carlos M, Akoi Bore Joseph, Raymond Koundouno Fara, Repits Johanna, Afrough Babak, Becker-Ziaja Beate, Hinzmann Julia, Mertens Marc, Vitoriano Ines, Hugh Logue Christopher, Böttcher Jan-Peter, Pallasch Elisa, Sachse Andreas, Bah Amadou, Cabeza-Cabrerizo Mar, Nitzsche Katja, Kuisma Eeva, Michel Janine, Holm Tobias, Zekeng Elsa Gayle, Cowley Lauren A, Garcia-Dorival Isabel, Hetzelt Nicole, Baum Jonathan Hans Josef, Portmann Jasmine, Carter Lisa, Yenamaberhan Rahel Lemma, Camino Alvaro, Enkirch Theresa, Singethan Katrin, Meisel Sarah, Mazzarelli Antonio, Kosgei Abigail, Kafetzopoulou Liana, Rickett Natasha Y, Patrono Livia Victoria, Ghebreghiorghis Luam, Arnold Ulrike, Colin Géraldine, Juchet Sylvain, Marchal Claire Levy, Kolie Jacques Seraphin, Beavogui Abdoul Habib, Wurr Stephanie, Bockholt Sabrina, Krumkamp Ralf, May Jürgen, Stoecker Kilian, Fleischmann Erna, Ippolito Giuseppe, Carroll Miles W, Koivogui Lamine, Magassouba N'Faly, Keita Sakoba, Gurry Céline, Drury Patrick, Diallo Boubacar, Formenty Pierre, Wölfel Roman, Di Caro Antonino, Gabriel Martin, Anglaret Xavier, Malvy Denis, Günther Stephan
Аннотация
METHODS: To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome.
RESULTS: The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors.
CONCLUSIONS: Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.